Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
Filed with ASX · · 5 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix Announces Record-Breaking Presence at EANM 2025
- CMS Grants Transitional Pass-Through Status for Gozellix
- Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
- Telix and FDA Agree Resubmission Pathway for Pixclara NDA
- Telix Provides Regulatory Update on TLX250-CDx
Later from Telix Pharmaceuticals
- TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging
- Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
- Telix to Participate in UBS and Jefferies Global Healthcare Conferences
- OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
- ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals